{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "GKOS",
  "name": "Glaukos Corporation",
  "url": "https://frontierpicks.com/dossiers/GKOS/",
  "json_url": "https://frontierpicks.com/dossiers/GKOS.json",
  "status": "HELD",
  "current_conviction": "MEDIUM",
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "Glaukos's two new eye-care launches, the iDose TR glaucoma implant and the Epioxa keratoconus therapy, lifted third-quarter 2026 sales 58% and moved the full-year guide up by $90 million. The open question is Medicare's still-pending iDose TR coverage decision, and the fourth-quarter report shows whether Epioxa's growth holds.",
  "invalidation_trigger": "A daily close below $205, below the $210.01 pre-market level of 2026-10-29, which would give back most of the post-earnings repricing; or a final Medicare LCD that sharply restricts iDose TR coverage.",
  "catalyst_date": "2026-11-09",
  "pick": {
    "id": "P-2026-10-30-GKOS",
    "conviction": "MEDIUM",
    "status": "open",
    "opened": "2026-10-30",
    "open_close": 237.6,
    "kill_level": 205,
    "kill_basis": "daily",
    "horizon_end": "2027-02-02",
    "last_date": "2026-10-30",
    "last_close": 237.6,
    "return_pct": 0,
    "spy_return_pct": 0,
    "excess_pp": 0,
    "kill_distance_pct": 15.902439024390237,
    "closed": null,
    "close_reason": null,
    "outcome": null,
    "scoreboard": "https://frontierpicks.com/track-record/"
  },
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Medicare contractors drafted proposed local coverage determinations for iDose TR in May 2026 and have one year from the draft to finalize or withdraw them; a final rule carries a 45-day period before it takes effect.",
    "Glaukos reports large gaps between GAAP and non-GAAP earnings; litigation expenses, including a resolution agreement with the University of California Regents, have weighed on GAAP results."
  ],
  "body_markdown": "## Current Thesis\nGlaukos has become a two-launch growth company. In the third quarter of 2026, the iDose TR drug-eluting glaucoma implant and the Epioxa keratoconus therapy pushed net sales up 58% to $211.0 million, and management raised 2026 guidance to $775–785 million. Two things settle the case: whether Medicare's contractors finalize a restrictive coverage rule for iDose TR, and whether Epioxa keeps growing past its first full quarter of reimbursement.\n\nThe company reported on 2026-10-28. It also gave preliminary 2027 net sales guidance of $1 billion, and management said on the call that this figure already includes downside scenarios for a restrictive iDose coverage rule. The narrative is accelerating. The report is two days old, and at least eight brokers raised price targets on 2026-10-29, per Benzinga.\n\nThe shares are crowded after the move. They closed at $242.48 on 2026-10-29, a 52-week high, with a 14-day relative strength index (RSI) of 92.9 and a three-month gain of 41.9% on adjusted daily closes. Those numbers describe the price, not the business. The company's view is that the next leg of the business case runs through reimbursement and the pace of the Epioxa rollout.\n\n## Bull Case\n- **Guidance raised by $90 million at the midpoint.** The 2026-10-28 release lifted 2026 net sales guidance to $775–785 million, up from $680–700 million. That range had itself been raised on 2026-07-29 from $620–635 million.\n- **iDose TR is now a large product line.** iDose TR sold about $76 million in the third quarter, per the 2026-10-28 earnings call. Management now expects full-year iDose revenue in the low $280 millions, against a prior $275–280 million.\n- **Epioxa ramped fast once reimbursement began.** Epioxa sold about $53 million in its first full quarter after its J-code (J2789, the Medicare billing code) took effect on 2026-07-01. Corneal Health revenue rose 154% to $59.0 million. On the call, management cited coverage of about 90% of commercial lives and more than 80% of Medicaid lives.\n- **Margins and the balance sheet strengthened.** Non-GAAP gross margin was 87.7% in the third quarter, up nearly 400 basis points year on year. Cash and investments rose to $339.8 million, from $289.3 million at the end of the second quarter, and the company reports no debt (2026-10-28 release).\n- **New clinical data supports iDose TR.** A randomized Phase 4 trial of iDose TR plus cataract surgery against cataract surgery alone met its primary endpoint, per the 2026-10-28 call. It showed an 11.1 mmHg mean eye-pressure reduction and a 3.6 mmHg incremental effect at three months.\n\n## Bear Case\n- **Medicare coverage for iDose TR is unresolved.** Medicare administrative contractors drafted proposed local coverage determinations (LCDs) for iDose TR in May 2026. They have one year from the draft to finalize or drop them, and management gave no update on 2026-10-28. In the third quarter, iDose growth came partly from fee-for-service Medicare patients in one contractor's jurisdiction, per the call.\n- **Profit is thin on a GAAP basis.** Third-quarter GAAP net income was $2.0 million, or $0.03 per diluted share, against non-GAAP earnings of $0.47. The quarter carried $14.1 million of expense tied to a resolution agreement with the Regents of the University of California and $5.9 million of other litigation costs (2026-10-28 release).\n- **The price has run past several targets.** The 2026-10-29 close of $242.48 is above the raised targets from Wells Fargo ($226), Stifel ($225), BTIG ($234) and Piper Sandler ($240), per Benzinga. It sits only modestly below Citigroup ($247), HC Wainwright ($248), Needham ($251) and Truist ($255).\n- **Epioxa is early in its rollout.** Management described the buy-and-bill channel, in which sites purchase the drug and then bill payers, as early on 2026-10-28. It said prior-authorization delays are typical of early rare-disease launches. One full reimbursed quarter is too short a history to show a steady growth rate.\n\n## Setup & Price Structure\nThe shares closed at $242.48 on 2026-10-29, their 52-week high, on adjusted daily closes. On the morning after the report, the shares traded at $210.01 in pre-market dealing, up 15.75%, and later rose as much as 30.8% to $237.26 during the regular session, per Benzinga. Benzinga put the market value at $10.7 billion at that price.\n\nThe 14-day RSI of 92.9 is far above the 70 level usually read as overbought, and the 41.9% three-month gain leaves the price well above its recent averages. The gap area matters most. A close back below the $210.01 pre-market level would mean the shares had given back most of the reaction to the report. The analyst targets raised on 2026-10-29 range from $225 to $255, so the stock already trades inside the range of Street targets.\n\n## Catalyst Calendar (next 30 days)\n\n- **On or before 2026-11-09:** The third-quarter Form 10-Q, which management said it expects to file by that date. It gives the full detail behind the litigation charges and the revenue lines.\n- **~2026-12-31 (est.):** Phase 2 results for the axitinib tyrosine kinase inhibitor retina program, and Phase 2 top-line results for the iLution Demodex blepharitis program. Management guided both to year-end on 2026-10-28.\n- **~2027-02 (est.):** The fourth-quarter 2026 report, which tests the $775–785 million guide and Epioxa's second full reimbursed quarter.\n\n## Elapsed catalysts\n\n- **Any date before ~2027-05 (est.):** Medicare contractors finalize or withdraw the iDose TR LCDs. A final rule carries a 45-day period before it takes effect, per the 2026-10-28 call. No date has been announced. *(passed 3d ago)*\n\n## What Would Change Our Mind\nA final Medicare LCD that sharply restricts iDose TR coverage in the fee-for-service jurisdictions driving its growth would break the case. So would an Epioxa quarter that fails to grow sequentially from about $53 million. Either would undercut the $1 billion 2027 outlook, which management built partly on both products. A cut to the 2026 sales guide at the fourth-quarter report would end the thesis outright.\n\nOn price, a daily close below $205 would put the shares under the $210.01 level where they traded before the regular session on 2026-10-29. At that point the market would have rejected most of the post-report repricing, whatever the fundamentals show.\n\n## Correlation Notes\nGlaukos's drivers are specific to the company: Medicare reimbursement for iDose TR, and payer and site rollout for Epioxa. Its link to medtech peers such as DexCom (DXCM) and Natera (NTRA) is loose. The closer influences are ophthalmology reimbursement policy and the surgical market for minimally invasive glaucoma surgery (MIGS), which management cited as a factor in its 2027 guide. As a high-growth, high-valuation healthcare name, the shares are likely to move with broader growth-stock sentiment and interest rates during sell-offs. That linkage would weaken if the stock held its post-report level through a broad growth-stock decline.",
  "first_seen": "2026-10-30",
  "last_analyzed": "2026-10-30T08:12:22+00:00",
  "last_synthesized": "2026-10-30",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}